Q-omics provides the consensus-scored MTCYBP4 profile across patient tissues and cancer cell-line models. MTCYBP4 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MTCYBP4 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MTCYBP4 RNA expression shows 9,821 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight MESO, KIRC, and KICH as cancer lineages where MTCYBP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP4 survival associations across molecular data types. MTCYBP4 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP4 RNA expression–survival associations across cancer types. High MTCYBP4 expression shows unfavorable associations in MESO, THYM, PCPG and KIRC, but favorable associations in KIRP and ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for MTCYBP4 RNA expression.
This table summarizes MTCYBP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP4 shows lower tumor expression in KIRC and STAD. The KIRC box plot shows higher MTCYBP4 RNA expression in normal versus tumor tissue (log2 FC = −0.147, t-test p = .007).
This table shows molecular features associated with MTCYBP4 in patient tissues and cancer cell lines. In patient samples, MTCYBP4 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set.
